Drug Discontinuation

Further to DrugAlert Vol 492, HPS Pharmacies wish to give notice that Pfizer has discontinued the following morphine tartrate ampoules:

DBL™ Morphine Tartrate
Morphine tartrate 120mg/1.5mL
ARTG 16324 

DBL™ Morphine Tartrate 400mg/5mL ampoules will continue to be available.

Morphine sulfate or morphine hydrochloride may be considered as alternatives. The following comparison table may be used to aid clinical decision making. The relevant product information should be reviewed for further information.

DBL™ Morphine Tartrate Injection DBL™ Morphine Sulfate Injection Juno Morphine Hydrochloride Injection
Approved indication Symptomatic relief of severe and intractable pains of various categories, in terminal cancer patients. Relief of moderate to severe pain not responsive to non-opioid analgesics.  It may also be used as a pre-operative medication and as an analgesic adjunct in general anaesthesia. Relief of moderate to severe pain not responsive to non-opioid analgesics; symptomatic relief of severe and intractable pain; terminal cancer pain; and as a pre-operative medication and analgesic adjunct in general anaesthesia
Composition Morphine tartrate trihydrate, sodium metabisulphite 1mg/mL in water for injections. The pH of the solution is 4.0-5.0. Isotonic, morphine sulfate pentahydrate and sodium chloride in water for injections. Hydrochloric acid (1N) is used to adjust the pH to 3.2-4.0. Morphine hydrochloride in water for injections. The pH of the solution is 3.0-5.0. Hydrochloric acid (0.1N) is used to adjust the pH of the solution.
Dose equivalence Morphine tartrate contains almost an equivalent amount of morphine base per milligram as morphine sulfate and morphine hydrochloride.1
Approved route of administration Subcutaneous, intramuscular and slow intravenous administration Subcutaneous, intramuscular and intravenous administration Subcutaneous, intramuscular or slow intravenous injection.
Strengths 400mg/5mL 5mg/1mL
10mg/1mL
15mg/1mL
30mg/1mL
10mg/1mL
50mg/5mL
20mg/1mL
100mg/5mL

Retain this notice in a prominent position, including in other related business units for one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.

Should you require further information regarding this matter, please contact Pfizer on 1800 675 229, or your pharmacist at HPS Pharmacies.

References:

Morphine Juno (morphine hydrochloride injection) Australian approved product information. South Yarra: Juno Pharmaceuticals. Approved August 2016.

Subscribe Knowledge Centre Updates

Enter your details to receive Knowledge Centre updates